Two Safe Stents at Two Years in High Bleeding Risk

There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual antiplatelet therapy (DAPT) for 12 months would not be advisable. Even though the European and American guidelines recommend 1 to 6 months for chronic and acute syndromes in this group, these are often complex PCI cases, which makes it a challenging decision. 

Dos stents seguros a dos años en el alto riesgo de sangrado

The LEADRES FREE had shown the superiority of the BioFreedom -polymer free coated with Biolimus A9- over bare metal stents, but this has not been shown for the rest of stents. 

As regards the Onyx, it was not inferior at 12 months, but it still hasn’t been tested beyond this period.  

The ONYX ONE study randomized high bleeding risk patients (HBR) to receiving the Resolute Onyx (ZES), (with 81- to 91-um struts) vs. BioFreedom (DCS) polymer free (with 12 um s struts). Post PCI they received DAPT or DAPT plus anticoagulation during the first 30 days followed by SAPT (ASA or P2Y12 inhibitors) plus antibiotics, according to physician criterion. 

It included 1003 patients receiving ZES and 933 DCS.

Safety primary end point was a composite of death, MI or definite or probable thrombosis at 12 months and effectiveness secondary end point was cardiac death, target vessel MI and ischemia driven revascularization at 12 months. They carried out a 2-year analysis. 

Read also: Coronary Bifurcation Lesions: MRS or PCI? 10-Year Mortality of the SYNTAX Study.

There were no differences in the populations, mean age was 74, 33% were women, 38% diabetic, 10% smokers, 25% had prior MI, 30% prior CABG, 31% atrial fibrillation.

52% presented acute coronary syndrome.

DAPT discontinuation after 30 days was similar in both groups, 77%  the second year (87% by the end of the first year), 65% receiving ASA as SAPT.

Read also: TRAPEUR Registry: Thrombus Trapping with Left Atrial Appendage Closure Device.

At 2-year followup, the primary end point for ZES and DCS was 21.2% vs. 20.7% (risk difference: 0.5%; 95% CI: -3.1%to 4.2%; P = 0.78), that is, there were no differences. The same happened for the secondary end point at 2 years: 22.1% vs. 21% (risk difference: 1.1%; 95% CI: -2.5% to 4.8%; P= 0.54) respectively.

Conclusion

Among patients with high bleeding risk treated with DAPT during 30 days and followed by SAPT, the Resolute ONYX ZES had similar evolution of safety and efficacy end points compared against the polymer free BioFreedom DCS. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients Final 2-Year Results From Onyx ONE.

Reference: Stephan Windecker, et al. J Am Coll Cardiol Intv 2022;15:1153–1163.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...